stoxline Quote Chart Rank Option Currency Glossary
  
Nutriband Inc. (NTRB)
4.06  0.08 (2.01%)    04-14 16:00
Open: 3.9449
High: 4.1
Volume: 4,910
  
Pre. Close: 3.98
Low: 3.9001
Market Cap: 49(M)
Technical analysis
2026-04-14 4:38:38 PM
Short term     
Mid term     
Targets 6-month :  4.99 1-year :  5.83
Resists First :  4.28 Second :  4.99
Pivot price 3.79
Supports First :  3.74 Second :  3.42
MAs MA(5) :  3.94 MA(20) :  3.81
MA(100) :  4.37 MA(250) :  5.9
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  78.4 D(3) :  71.1
RSI RSI(14): 55.3
52-week High :  11.67 Low :  3.42
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NTRB ] has closed below upper band by 11.2%. Bollinger Bands are 26.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.11 - 4.12 4.12 - 4.14
Low: 3.86 - 3.88 3.88 - 3.89
Close: 4.03 - 4.06 4.06 - 4.09
Company Description

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Headline News

Tue, 07 Apr 2026
Abuse-deterrent fentanyl patch at Nutriband (NASDAQ: NTRB) targets $80M-$200M - Stock Titan

Mon, 30 Mar 2026
Nutriband seeks FDA review for fentanyl patch designed to deter abuse - Stock Titan

Mon, 30 Mar 2026
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch - GlobeNewswire

Wed, 18 Mar 2026
Nutriband (NASDAQ: NTRB) Secures Costa Rica Approval for Kinesiology Tape Line - The Globe and Mail

Thu, 05 Mar 2026
What’s Driving Nutriband Shares Higher Today? - Stocktwits

Thu, 29 Jan 2026
The past five years for Nutriband (NASDAQ:NTRB) investors has not been profitable - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 12 (M)
Held by Insiders 4.91e+006 (%)
Held by Institutions 74.3 (%)
Shares Short 194 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -9.03e+006
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 121.3 %
Return on Equity (ttm) -55.3 %
Qtrly Rev. Growth 2.28e+006 %
Gross Profit (p.s.) -24.69
Sales Per Share -72.39
EBITDA (p.s.) 406016
Qtrly Earnings Growth -3.1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.06
Price to Cash Flow 12.31
Stock Dividends
Dividend 0
Forward Dividend 199150
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android